Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2007 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2028

• 468 Active
• 1104 Finished

Grants per year

Search results

• Development of OncoLink: A Web-Based irAE Monitoring Platform

  Yanez, B. R., Mohindra, N. A., Penedo, F. J. & Sosman, J. A.

  American Cancer Society, Bristol-Myers Squibb Company

  7/1/18 → 12/31/20

  Project: Research project

  • Kidney Neoplasms 100%
  • Survival 49%
  • Oncologists 49%
  • Colitis 45%
  • Exanthema 44%

• Prot #PCYC-1127-CA: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom’s Macroglobulinemia

  Ma, S.

  PPD Development, Pharmacyclics, Inc.

  10/14/14 → 12/31/20

  Project: Research project

• Prot# H4320s//NU 10C03: Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

  Kumthekar, P. U., Gradishar, W. J. & Raizer, J. J.

  Genentech, Inc.

  4/22/11 → 12/31/20

  Project: Research project

• Prot #GO28754: A Phase II, Multicenter, Single-Arm Study of MPDL3280a in Patients with PD-L1–Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  Mohindra, N. A.

  INC Research, LLC, Genentech, Inc.

  12/13/13 → 12/31/20

  Project: Research project

• Prot #KCP-330-009: A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  Karmali, R. & Kaplan, J. B.

  Clinipace, Inc., Karyopharm Therapeutics Inc.

  12/23/14 → 12/23/20

  Project: Research project

• NU 17Z01 (Freenome) - Blood Biomarker Analysis in Patients with Solid Tumors or Lymphoma

  Chae, Y. K.

  Freenome Holdings, Inc.

  12/21/17 → 12/21/20

  Project: Research project

• NU 17Z01 (Lexent Bio) - Blood Biomarker Analysis in Patients with Solid Tumors or Lymphoma

  Chae, Y. K.

  Lexent Bio, Inc.

  12/14/17 → 12/14/20

  Project: Research project

• Prot #BTCRC-GI13-002: An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium

  Benson III, A. B.

  Hoosier Cancer Research Network, Inc., Millennium Pharmaceuticals, Inc

  11/14/17 → 11/14/20

  Project: Research project

• DRUG IMCGP100-202 -A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma

  Chandra, S.

  DrugDev Inc., Immunocore Limited

  11/14/17 → 11/14/20

  Project: Research project

• Nanotechnology to Diagnose, Prevent, and Treat Cardiovascular Disease

  Thaxton, C. S., Dravid, V. P., Gordon, L. I. & Mutharasan, R. K.

  Nanyang Technological University

  11/1/14 → 10/31/20

  Project: Research project

  • Lipoproteins 100%
  • Nanoparticles 57%
  • Nanotechnology 47%
  • Theranostics 45%
  • Medical nanotechnology 40%

• Prot #WI245493: SIRT3 Expression as a Novel Predictive Biomarker of Response to Palbociclib in Hormone-Receptor Positive, Endocrine-Resistant Luminal Breast Cancer

  Cristofanilli, M. & Vasilopoulos, A.

  Pfizer Inc.

  10/14/19 → 10/14/20

  Project: Research project

  • palbociclib 100%
  • Breast Neoplasms 31%
  • Hormones 28%
  • Biomarkers 26%
  • Fulvestrant 25%

• Prot #NC-6004-008: Phase I/II Clinical Trial of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck

  Matsangou, M.

  PPD Investigator Services, LLC, NanoCarrier Co., Ltd.

  10/10/17 → 10/10/20

  Project: Research project

• Prot #DV3-MEL-01: A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  Chandra, S.

  PRA Health Sciences, Dynavax Technologies Corporation

  10/3/17 → 10/3/20

  Project: Research project

• Targeting alphaB-Crystallin in Basal-like Breast Cancer

  Gradishar, W. J.

  University of Wisconsin-Madison, Breast Cancer Research Foundation

  10/1/19 → 9/30/20

  Project: Research project

  • Crystallins 100%
  • Breast Neoplasms 62%
  • Neoplasm Metastasis 37%
  • Breast 23%
  • Brain 22%

• Community Counts: Public Health Surveillance for Bleeding Disorders

  Zakarija, A.

  Great Lakes Hemophilia Foundation, Centers for Disease Control and Prevention

  9/30/15 → 9/29/20

  Project: Research project

  • Public Health Surveillance 100%
  • Hemophilia A 91%
  • Hemorrhage 65%
  • Centers for Disease Control and Prevention (U.S.) 55%
  • Hemostasis 54%

• Prot #2125-MEL-301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

  Chandra, S.

  Medpace Clinical Research LLC, Idera Pharmaceuticals, Inc.

  4/9/19 → 9/23/20

  Project: Research project

• Prot #2215-CL-9100: A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3 Mutated AML in Complete Remission (CR) with M

  Frankfurt, O.

  INC Research, LLC, Astellas Pharma Global Development, Inc.

  9/20/17 → 9/20/20

  Project: Research project

• Prot #1101-HEM-101: A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients with Relapsed or Refractory Hematologic Malignancies

  Dinner, S. N.

  Translational Drug Development, LLC, FORMA Therapeutics, Inc.

  9/8/17 → 9/8/20

  Project: Research project

• Prot #13676-01: A Phase 1 Multidose Study To Evaluate The Safety And Tolerability Of XmAb®13676 In Patients With Cd20-Expressing Hematologic Malignancies

  Karmali, R.

  Chiltern International, Inc., Xencor, Inc.

  9/1/17 → 9/1/20

  Project: Research project

• Aberrant megakaryopoiesis in the myeloproliferative neoplasms.

  Crispino, J. D.

  National Heart, Lung, and Blood Institute

  5/1/17 → 8/31/20

  Project: Research project

  • Megakaryocytes 100%
  • Primary Myelofibrosis 69%
  • Ribosomes 21%
  • Polycythemia 17%
  • Neoplasms 14%

• Mechanisms of Leukemogenesis in Down Syndrome

  Crispino, J. D. & Zhao, C.

  National Cancer Institute

  5/1/17 → 8/31/20

  Project: Research project

  • Chromosomes, Human, Pair 21 100%
  • Down Syndrome 79%
  • Leukemia, Megakaryoblastic, Acute 59%
  • B-Lymphoid Precursor Cells 45%
  • Chromatin Assembly and Disassembly 44%

• CCHEC Research and Education Core

  Moreira, J., Yanez, B. R. & Penedo, F. J.

  National Cancer Institute

  9/24/15 → 8/31/20

  Project: Research project

  • cancer 100%
  • education 20%
  • equity 17%
  • research project 16%
  • health 13%

• Tissue transglutaminase fibronectin interaction in ovarian cancer stem cells

  Condello, S. & Matei, D. E.

  Northwestern Memorial Hospital

  9/1/17 → 8/31/20

  Project: Research project

  • Neoplastic Stem Cells 100%
  • transglutaminase 2 87%
  • Ovarian Neoplasms 85%
  • Fibronectins 73%
  • Wnt Receptors 47%

• Research supplement for aberrant megakaryopoiesis in the myeloproliferative neoplasms

  Crispino, J. D.

  National Heart, Lung, and Blood Institute

  5/1/17 → 8/31/20

  Project: Research project

  • Megakaryocytes 100%
  • Primary Myelofibrosis 69%
  • Ribosomes 21%
  • Polycythemia 17%
  • Neoplasms 14%

• Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer

  Mirkin, C. A., Catalona, W. J., Kuzel, T. M., Lee, A. & Zhang, B.

  Prostate Cancer Foundation

  8/31/17 → 8/30/20

  Project: Research project

  • prostatic neoplasms 100%
  • cancer vaccines 68%
  • nucleic acids 54%
  • antigens 54%
  • immune response 45%